2021 research period for North America is officially open
March 24, 2021
Research team is now accepting firm submissions, due June 1
US
Corporate
| General Corporate — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Hogan Lovells |
| Latham & Watkins |
| Ropes & Gray |
| WilmerHale |
| General Corporate — Recommended |
|---|
| Arnold & Porter |
| Covington & Burling |
| Dechert |
| Fenwick & West |
| Gibson Dunn & Crutcher |
| Jones Day |
| Morgan Lewis & Bockius |
| Sidley Austin |
| Wilson Sonsini Goodrich & Rosati |
Hatch-Waxman Patent Litigation (Generic)
| Hatch-Waxman Patent Litigation (Generic) — Highly Recommended |
|---|
| Goodwin Procter |
| Knobbe Martens |
| Rakoczy Molino Mazzochi Siwik |
| Sterne Kessler Goldstein & Fox |
| Wilson Sonsini Goodrich & Rosati |
| Winston & Strawn |
| Hatch-Waxman Patent Litigation (Generic) — Recommended |
|---|
| Axinn Veltrop & Harkrider |
| Greenberg Traurig |
| Morrison & Foerster |
| Perkins Coie |
| Robins Kaplan |
| Rothwell Figg Ernst & Manbeck |
| Taft Stettinius & Hollister |
| Willkie Farr & Gallagher |
Licensing & Collaboration
| Licensing & Collaboration — Highly Recommended |
|---|
| Cooley |
| Covington & Burling |
| Goodwin Procter |
| Latham & Watkins |
| Ropes & Gray |
| WilmerHale |
| Wilson Sonsini Goodrich & Rosati |
| Licensing & Collaboration — Recommended |
|---|
| Baker McKenzie |
| Dechert |
| Fenwick & West |
| Hogan Lovells |
| Jones Day |
| King & Spalding |
| Morgan Lewis & Bockius |
| Sidley Austin |
Patent Prosecution
Patent Strategy & Management
| Patent Strategy & Management — Recommended |
|---|
| Arnold & Porter |
| Dechert |
| Fenwick & West |
| Foley & Lardner |
| Greenberg Traurig |
| Hamilton Brook Smith & Reynolds |
| Leydig Voit & Mayer |
| McDonnell Boehnen Hulbert & Berghoff |
| Morgan Lewis & Bockius |
| Venable |
| WilmerHale |
Venture Capital
| Venture Capital — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Latham & Watkins |
| Wilson Sonsini Goodrich & Rosati |
| Venture Capital — Recommended |
|---|
| Gunderson Dettmer |
| Hogan Lovells |
| Mintz Levin Cohn Ferris Glovsky and Popeo |
| Ropes & Gray |
| WilmerHale |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Bellomy, Mark | Financial & Corporate | Licensing & Collaboration | Boston |
| Clark, Kenneth A | Financial & Corporate | Mergers & Acquisitions | Palo Alto, San Diego |
| Creighton, Susan | Non-IP Litigation & Enforcement | Antitrust | Washington, D.C. |
| Edvalson, Ian | Financial & Corporate | Venture Capital, Licensing & Collaboration, Mergers & Acquisitions | Palo Alto |
| Heslin, James M | Intellectual Property | Patent Prosecution, Patent Strategy & Management | Palo Alto |
| Hostetler, Michael | Intellectual Property | Patent Prosecution | San Francisco |
| Ishii, Robert T | Financial & Corporate | Mergers & Acquisitions | San Francisco |
| Koeppen, Dan | Financial & Corporate | Corporate, Mergers & Acquisitions | San Diego |
| McGlynn, J Casey | Financial & Corporate | Corporate, Venture Capital, Mergers & Acquisitions | Palo Alto |
| Norviel, Vern | Intellectual Property | Patent Prosecution, Patent Strategy & Management | San Francisco |
| Oettinger, Philip | Financial & Corporate | Corporate | Palo Alto |
| Silber, Seth | Non-IP Litigation & Enforcement | Antitrust, White-Collar/Govt. Investigations | Washington, D.C. |
| Waters, Martin J | Financial & Corporate | Corporate, Venture Capital, Licensing & Collaboration, Mergers & Acquisitions | San Francisco |
| Wehrli, John E | Financial & Corporate | Licensing & Collaboration, Mergers & Acquisitions | San Diego |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Financial & Corporate
Wilson Sonsini Goodrich & Rosati
A Silicon Valley institution, Wilson Sonsini Goodrich & Rosati is highly regarded for its robust financial and corporate practice focused on emerging life sciences companies. The firm assists clients in a number of matters involving transactions, licensing, collaboration, and venture capital.
Ian Edvalson advises a number of public and private life sciences companies on licensing agreements and strategic collaborative transactions. Among his recent clients, Edvalson represented CG Oncology in its collaboration agreement with Kissei Pharmaceutical for its oncolytic immunotherapy drug. In addition, Edvalson advised Mammoth Pharmaceuticals in a collaboration deal with GlaxoSmithKline to accelerate CRISPR-based Covid-19 diagnostics test.
Kenneth Clark is well known in the industry and has significant experience assisting clients with licensing agreements and collaborations, among other areas. Recently, Clark advised ORIC Pharmaceuticals in its $138 million IPO as well as IGM Biosciences with its offering which totaled $201.3 million.
Robert Ishii is based in San Francisco and primarily focuses on mergers and acquisitions in the life sciences space. Ishii was recently part of a Wilson Sonsini team that advised Forte Biosciences in its merger agreement with Tocagen, a biopharmaceutical company focused on gene therapy.
Intellectual Property
Wilson Sonsini Goodrich & Rosati
Bay Area staple Wilson Sonsini Goodrich & Rosati is highly recommended in generic Hatch-Waxman litigation and patent strategy. The firm is also notable for its expertise in patent filing and prosecution.
Vern Norviel is a preeminent patent strategist for clients in the life sciences industry and leader of the firm's patents and innovations counseling practice group. He specializes in patent prosecution, strategy and portfolio development. Norviel recently assisted client 10x Genomics in patent matters related to its $50 million Series D financing.
San Francisco partner Michael Hostetler was named the 2020 Patent Strategy Attorney of the Year in California for his notable year of practice assisting clients with portfolio management and deal-oriented advice. Among his many recent representations, Hostetler was active for Crinetics Pharmaceuticals in patent matters related to a recent public offering, and Horizon Therapeutics as IP counsel in its acquisition of Curzion Pharmaceuticals. James Heslin is an expert in the medical device field, drawing on more than 20 years of experience as a patent counselor.